<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03050164</url>
  </required_header>
  <id_info>
    <org_study_id>KL031-BE-01</org_study_id>
    <nct_id>NCT03050164</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Gefitinib Tablets Under Fasting Conditions</brief_title>
  <official_title>Single-dose, Open-label, Randomized, 2-way Crossover Bioequivalence Study of Gefitinib Tablets Under Fasting Conditions in Chinese Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hunan Kelun Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hunan Kelun Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study design is an Open-Label，Randomized, Single-Dose, 2-way Crossover Bioequivalence&#xD;
      Study. During each session, the subjects will be administered a single dose of 250mg&#xD;
      Gefitinib Tablet (one Gefitinib Tablet 250mg of Hunan Kelun or one Iressa® Tablet 250mg of&#xD;
      AstraZeneca) under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open-Label，Randomized, Single-Dose, 2-way Crossover Bioequivalence Study. During each&#xD;
      session, the subjects were randomly assigned in a 1:1 ratio to receive a single 250-mg dose&#xD;
      of either the test formulation(Hunam Kelun) or the reference formulation(Iressa®&#xD;
      Astrazeneca), and vice versa, with a 21-day washout period between administration periods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 8, 2016</start_date>
  <completion_date type="Actual">November 4, 2016</completion_date>
  <primary_completion_date type="Actual">November 4, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameter：Cmax</measure>
    <time_frame>before drug delivery through 216 hours after dosing</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter：AUC</measure>
    <time_frame>before drug delivery through 216 hours after dosing</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Bioequivalence Study</condition>
  <arm_group>
    <arm_group_label>Gefitinib Tablet 250mg of Hunan Kelun</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the study session, healthy subjects were orally administered a single dose of Gefitinib Tablet 250mg of Hunan Kelun under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iressa® Tablet 250mg of AZN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During the study session, healthy subjects were orally administered a single dose of Iressa® Tablet 250mg of AZN under fasting conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib Tablet 250mg of Hunan Kelun</intervention_name>
    <description>Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered after a 10-hour overnight fast.</description>
    <arm_group_label>Gefitinib Tablet 250mg of Hunan Kelun</arm_group_label>
    <arm_group_label>Iressa® Tablet 250mg of AZN</arm_group_label>
    <other_name>A031</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iressa® Tablet 250mg of AZN</intervention_name>
    <description>Single dose of Iressa® Tablet 250mg of AZN was administered after a 10-hour overnight fast.</description>
    <arm_group_label>Gefitinib Tablet 250mg of Hunan Kelun</arm_group_label>
    <arm_group_label>Iressa® Tablet 250mg of AZN</arm_group_label>
    <other_name>Iressa®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male subjects.&#xD;
&#xD;
          2. At least 18 years of age .&#xD;
&#xD;
          3. Weight at least 50kg and body mass index between 19 and 26 kg/m2.&#xD;
&#xD;
          4. Informed consent and voluntary to sign a written informed consent.&#xD;
&#xD;
          5. Can communicate with researchers and complete the study in accordance with the&#xD;
             provisions of the research.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Abnormal diagnostic findings, and clinical significances determined by researchers&#xD;
             (physical examination,vital sign, ECG,X-ray,blood routine examination, urine routine&#xD;
             examination,blood biochemical examination and coagulation test).&#xD;
&#xD;
          2. Having functional gastrointestinal disease or inadequate secretion of gastric acid or&#xD;
             is treated for a acid suppression. Which including gastro upset, dyspepsia, gastritis,&#xD;
             gastric ulcer, duodenal ulcer, gastric secrete melanoma, etc.&#xD;
&#xD;
          3. Taking drugs that alter the environment of the gastrointestinal，especially alter the&#xD;
             gastrointestinal pH，within 30 days before the first dose. Such as Proton pump&#xD;
             inhibitors：thiophene, omeprazole, lansoprazole, esomeprazole, etc . and H2 antagonist&#xD;
             ranitidine：cimetidine, famotidine, etc .and antacids hydrogen carbonate Sodium,&#xD;
             magnesium oxide, aluminum hydroxide, magnesium trisilicate, etc .and gastric mucosal&#xD;
             protective agent：sucralfate，and so on.&#xD;
&#xD;
          4. Not comply with a unified diet or has swallowing difficulties.&#xD;
&#xD;
          5. Allergic to any ingredient or excipients of the study drug.&#xD;
&#xD;
          6. History of gastrointestinal disorders and severe liver and kidney diseases ，which&#xD;
             affect the absorption or metabolism of drugs so far.&#xD;
&#xD;
          7. History of ocular surface damaging diseases (such as corneal perforation, ulcers,&#xD;
             etc.).&#xD;
&#xD;
          8. History of serious blood diseases.&#xD;
&#xD;
          9. With skin, cardiovascular, liver, kidney, digestive, neurological, psychiatric,&#xD;
             metabolic disorders, or any other disease that can interfere with the results of the&#xD;
             trial.&#xD;
&#xD;
         10. History of long-term excessive drinking (more than 8 cups a day, 1 cup = 250 mL) of&#xD;
             tea, coffee or caffeinated beverages，or 48 hours before the first dose intake of any&#xD;
             food or drink containing caffeine (such as coffee, tea, chocolate, etc.).&#xD;
&#xD;
         11. Ingested any drinks or foods that are rich in xanthine and grapefruit or affect the&#xD;
             drug absorption, distribution, metabolism and excretion.&#xD;
&#xD;
         12. A positive result in breath alcohol test or previous alcohol abuse (ie, men drink more&#xD;
             than 28 standard units a week [1 standard unit defined as containing 14 grams of&#xD;
             alcohol, such as would be found in a standard shot of hard liquor, a 12-ounce bottle&#xD;
             of beer, or a 5-ounce glass of wine] Or regular drinking(more than 14 standard units&#xD;
             of alcohol per week) within 6 months before the trial.&#xD;
&#xD;
         13. Daily intake of more than 3 cigarettes from 3 months before the study to 48 hours&#xD;
             before the first dose or intake of tobacco or any type of tobacco product within 48&#xD;
             hours before the first dose.&#xD;
&#xD;
         14. Taking drugs that interact with gefitinib （such as CYP3A4 inhibitors： itraconazole,&#xD;
             ketoconazole, clotrimazole, Ritonavir, etc .and CYP3A4/5 inducers：rifampicin,&#xD;
             carbamazepine, phenobarbital, phenytoin, dexamethasone, etc .and CYP2D6&#xD;
             inhibitors：Fluoxetine, paroxetine , etc .） within 30 days before the first dose. And&#xD;
             use of any prescription drugs, non-prescription drugs, Chinese herbal medicine, health&#xD;
             products within 14 days before the first dose.&#xD;
&#xD;
         15. Volunteer in any other clinical drug study or taking any clinical trial drug within 3&#xD;
             months prior to this study.&#xD;
&#xD;
         16. Blood donation or lost more than 450mL blood within 3 months prior to the study，or has&#xD;
             a plan to donate blood or blood components within the study period or within 3 months&#xD;
             after the end of study.&#xD;
&#xD;
         17. Suffering from a serious illness or having undergone major surgical procedures within&#xD;
             1 years before the firs dose.&#xD;
&#xD;
         18. Abnormal blood coagulation, or having a known tendency of severe bleeding.&#xD;
&#xD;
         19. A positive result in drug test or existing drug abuse (eg, morphine, marijuana,&#xD;
             methamphetamine, dimethylene bisoxamine amphetamines, ketamine, etc.) within 1 year&#xD;
             prior to the trial.&#xD;
&#xD;
         20. A positive result in hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV)&#xD;
             antibodies, a syphilis test, or an human immunodeficiency virus (HIV) test.&#xD;
&#xD;
         21. Having fertility planning or reluctant to take appropriate contraceptive during the&#xD;
             study or within 6 months after the study.&#xD;
&#xD;
         22. Other unfavorable factors diagnosed by investigators.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>January 21, 2017</study_first_submitted>
  <study_first_submitted_qc>February 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2017</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

